PharmiWeb.com - Global Pharma News & Resources
05-Jun-2019

Lonza to Host New Webinar Titled "Know Your Enemy: Mycoplasma Contamination in Cell Culture"

Walkersville, MD (USA) / Basel (CH), 5 June 2019 – On 18 June 2019, Lonza will host a free 60-minute webinar on mycoplasma contamination and how Lonza’s MycoAlert™ Assay enables simple and fast detection of mycoplasma contaminants in cell cultures.

Mycoplasma contamination of cell cultures can be detrimental to the reliability, reproducibility and consistency of experimental results. However, despite the severe consequences, mycoplasma contamination is often overlooked, especially since mycoplasma are not visible to the naked eye, even at high concentrations. As such, they may remain undiscovered for months. Regular testing of cell cultures is thus key to minimize the contamination potential.

Titled "Know Your Enemy: Mycoplasma Contamination in Cell Culture," the webinar will be presented by Isabella Drewelus, Scientific Support Specialist at Lonza. During the webinar, she will discuss: 
  • What mycoplasma are and how they get into cell cultures
  • The potential impact of mycoplasma on cells and the generated scientific data
  • How Lonza’s MycoAlert™ Assay facilitates quick and simple detection of mycoplasma contamination in cell cultures
More information about attending the webinar is available here.

Date: Tuesday, 18 June, 2019 

8 AM PDT (Los Angeles)
11 AM EDT (New York)
4 PM BST (London)
5 PM CEST (Berlin)

Further information can be found on Lonza’s Mycoplasma Contamination application page. By registering interest in the webinar, participants will also receive a link once it is available to view "on demand" via the Lonza website. 

More information about Lonza’s upcoming and on-demand webinars is available via www.lonza.com/webinars.

About Lonza 
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma & Biotech segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases. 

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live. 

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.

Lonza Contact Information
Petra Haberkamm
Manager Marketing Communications
Lonza Cologne GmbH
Tel +49 221 991990
petra.haberkamm@lonza.com

Constance Ward 
Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Editor Details

Last Updated: 06-Jun-2019